SNIPR receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR's microbial gene therapy platform to improve EED in pregnant women from low- and middle-income countries (LMICs).
SNIPR receives funding for the development of CRISPR-medicines to improve Environmental Enteric Dysfunction (EED) in pregnant women
Previous
Previous
SNIPR receives up to EUR 20 million from European Investment Bank (EIB) to advance therapies against microbial resistance
Next
Next